Charles G A, Schittecatte M, Rush A J, Panzer M, Wilmotte J
Centre Hospitalier Vincent Van Gogh, Charleroi, Belgium.
J Affect Disord. 1989 Nov-Dec;17(3):271-8. doi: 10.1016/0165-0327(89)90010-4.
We assessed the length and the quality of remission of 13 unipolar endogenous depressed patients, DST non-suppressors before treatment, in a 2-year prospective study. During this period, we recorded stressful life events. Persistent dexamethasone non-suppression, after treatment and complete clinical recovery, correlated highly with early clinical relapse. All six non-normalizers but only one normalizer were rehospitalized within the following 2 years for a major depressive relapse. Persistent DST non-suppression was unrelated to any impact of drug discontinuation, the occurrence of stressful life events or the length of illness-free intervals in the patient's prior course of illness. Persistent DST non-suppression appears to have significant prognostic value.
在一项为期两年的前瞻性研究中，我们评估了13例单相内源性抑郁症患者（治疗前地塞米松抑制试验[DST]不被抑制者）的缓解期长度和质量。在此期间，我们记录了应激性生活事件。治疗后临床完全康复但地塞米松持续不被抑制与早期临床复发高度相关。在接下来的两年内，所有6例DST未恢复正常者中有6例因重度抑郁复发再次住院，而DST恢复正常者中只有1例再次住院。持续的DST不被抑制与停药的任何影响、应激性生活事件的发生或患者既往病程中无病间期的长度均无关。持续的DST不被抑制似乎具有显著的预后价值。
